Fragment / CJC-1295 (No DAC) / Ipamorelin Blend is a research peptide formulation combining three well-studied synthetic peptides commonly examined in growth hormone and endocrine signaling research: Fragment (176–191), CJC-1295 without Drug Affinity Complex (No DAC), and Ipamorelin. Fragment (176–191) is a modified C-terminal fragment of human growth hormone, while CJC-1295 (No DAC) is a growth hormone–releasing hormone (GHRH) analog and Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R) agonist. Together, this blend is formulated for laboratory research focused on growth hormone signaling, metabolic pathways, and coordinated endocrine response mechanisms.
Prior to the targeted synthesis and study of these peptides, research into growth hormone modulation and metabolic signaling relied largely on less specific hormonal interventions and generalized secretagogues. In controlled research settings, Fragment (176–191) has been studied for its role in lipid metabolism–related signaling pathways. CJC-1295 (No DAC) has been researched for its ability to stimulate endogenous growth hormone release through GHRH receptor activation while maintaining a shorter duration of action compared to DAC-bound variants. Ipamorelin has been examined for its selective receptor activity and minimal interaction with other pituitary hormones. The combination allows researchers to explore complementary mechanisms involved in growth hormone pulsatility, metabolic signaling, and endocrine coordination.
Currently, the Fragment / CJC-1295 (No DAC) / Ipamorelin Blend is being investigated for potential applications in metabolic research models, endocrine pathway analysis, recovery-related signaling studies, and age-associated hormone regulation research. Additional investigation continues into its role in downstream anabolic and metabolic signaling processes, circadian hormone release patterns, and coordinated pituitary response mechanisms. Due to the complementary research interest of these peptides, this blend remains a compelling subject for ongoing laboratory investigation.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
The Fragment 176-191, CJC-1295 (No DAC), Ipamorelin Blend is structured for laboratory research investigating metabolic signaling pathways, growth hormone axis communication, and endocrine marker behavior within controlled experimental models. By combining a growth hormone fragment peptide with a GHRH analog and a growth hormone secretagogue, researchers can examine how multiple signaling inputs influence metabolic and endocrine pathways simultaneously.
Multi-peptide experimental protocols such as this blend are often used in research environments where investigators want to analyze interactions between GH-axis signaling and metabolic marker activity. Because combination peptide studies introduce additional variables, well-designed experimental frameworks typically emphasize strict endpoint definitions, consistent environmental conditions, and detailed documentation to maintain reproducibility.
Fragment 176-191, CJC-1295 (No DAC), Ipamorelin Blend – Research Specifications:
| Format | Lyophilized peptide blend (research format) |
| Contents | Fragment 176-191 + CJC-1295 (No DAC) + Ipamorelin |
| Purity / Identity | Research-grade; refer to Certificate of Analysis (COA) for lot-specific analytical data |
| Source | Peptide synthesis with standardized processing and QC documentation |
| Appearance | Powder (lyophilized) |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, and moisture. Maintain lot integrity per laboratory SOPs. |
| Research Use Only | Supplied exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. |
Fragment 176-191 is a modified fragment of the human growth hormone sequence that is frequently referenced in metabolic research involving lipid metabolism and adipose tissue signaling pathways. In laboratory models, this peptide fragment is sometimes evaluated for its potential influence on metabolic marker behavior independent of broader GH-axis endocrine effects.
CJC-1295 without DAC is a modified growth hormone–releasing hormone analog studied in research environments exploring pulsatile GH signaling patterns. Because the compound lacks the Drug Affinity Complex (DAC) modification present in some long-acting variants, researchers often use it in experimental models where shorter signaling windows and clearer pulse-response patterns are desirable.
Ipamorelin is a growth hormone secretagogue that interacts with ghrelin receptor pathways and is frequently used in laboratory models examining pituitary response mechanisms and endocrine signaling cascades. Combining these peptides allows researchers to evaluate how metabolic signaling variables interact with growth hormone–related pathways in multi-variable experimental systems.
Individual compound information can also be referenced through the product pages for Fragment 176-191, CJC-1295 (without DAC), and Ipamorelin.
Important Research Notice: Nordsci products are supported by lot-level analytical documentation. Certificates of Analysis are available to support internal audits, method alignment, and reproducibility across research studies.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
Fragment 176-191 is often studied in laboratory models investigating metabolic signaling pathways related to lipid metabolism. In controlled research environments, investigators may evaluate how metabolic markers respond when this peptide fragment is combined with GH-axis signaling variables.
CJC-1295 (No DAC) and Ipamorelin are frequently used in GH-axis research examining pulsatile hormone release patterns. When included in a blended experimental protocol, researchers may observe how endocrine marker fluctuations change across timed sampling intervals.
This blend enables researchers to evaluate interactions between metabolic signaling variables and endocrine pathway responses. Comparative research designs may analyze whether combined signaling inputs produce additive or synergistic changes in downstream biomarker profiles.
Many peptide research programs include both blended and single-compound experimental conditions. This research structure allows investigators to determine whether observed effects arise from individual signaling pathways or the interaction of multiple peptides.
The Fragment 176-191, CJC-1295 (No DAC), Ipamorelin Blend should be handled according to standard peptide laboratory procedures emphasizing contamination prevention, proper storage conditions, and detailed experimental documentation. Maintaining stable laboratory environments helps improve reproducibility across research studies.
Protocol Design Considerations: Growth hormone signaling and metabolic marker experiments are sensitive to circadian rhythm timing, baseline metabolic status, environmental conditions, and stress variables. Standardized sampling windows and controlled laboratory environments are essential for reliable data interpretation.
Note: The information above is provided solely as a research reference summary. All experimental work must be conducted by qualified researchers in appropriate laboratory facilities.
Each lot of this peptide blend includes a Certificate of Analysis verifying peptide identity and quality parameters. These analytical reports assist laboratories with procurement verification, regulatory documentation, and reproducibility tracking across experimental studies.
Laboratories sourcing peptides for metabolic and endocrine signaling research typically prioritize traceable documentation, reliable manufacturing processes, and strict quality-control standards. Nordsci Peptides provides research-grade peptide materials supported by analytical documentation and standardized synthesis protocols designed to support reproducible laboratory research.
IMPORTANT: This product is supplied exclusively for laboratory research use. It is not approved for human consumption or clinical application. Researchers are responsible for complying with all applicable regulatory and institutional guidelines.
